

# Baohui Han

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3395408/publications.pdf>

Version: 2024-02-01

241  
papers

13,176  
citations

101384

36  
h-index

25716

108  
g-index

260  
all docs

260  
docs citations

260  
times ranked

12585  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1417-1424.	1.2	4
2	A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II Study. <i>Clinical Cancer Research</i> , 2022, 28, 1127-1135.	3.2	9
3	Novel blood-based hypomethylation of SH3BP5 is associated with very early-stage lung adenocarcinoma. <i>Genes and Genomics</i> , 2022, 44, 445-453.	0.5	5
4	The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma. <i>Cancer Medicine</i> , 2022, 11, 1299-1309.	1.3	6
5	Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: A retrospective observational study. <i>Thoracic Cancer</i> , 2022, , .	0.8	6
6	Combined large cell neuroendocrine carcinoma: clinical characteristics, prognosis and postoperative management. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	0.6	4
7	Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 28-39.	0.7	5
8	Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 807575.	2.2	4
9	Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study). <i>BMC Cancer</i> , 2022, 22, 294.	1.1	1
10	Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 2022, 13, 812555.	1.6	0
11	Multi-Omics Signatures Identification for LUAD Prognosis Prediction Model Based on the Integrative Analysis of Immune and Hypoxia Signals. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 840466.	1.8	0
12	The centromere-associated protein CENPU promotes cell proliferation, migration, and invasiveness in lung adenocarcinoma. <i>Cancer Letters</i> , 2022, 532, 215599.	3.2	4
13	FBYB methylation in peripheral blood as a potential marker for the early-stage lung cancer: a case-control study in Chinese population. <i>Biomarkers</i> , 2022, 27, 79-85.	0.9	0
14	Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial. <i>Cancer Medicine</i> , 2022, 11, 1081-1087.	1.3	8
15	ASO Visual Abstract: Different Characteristics and Survival Between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0
16	Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 5666-5678.	0.7	3
17	ASO Author Reflections: Pure and Combined Surgically Resected Large Cell Neuroendocrine Carcinoma of Lung: Could They be Evaluated as a Single Entity?. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
18	Subgroup analysis in patients (pts) with non-squamous (N-Sq), EGFR-wild type (wt), second/third-line NSCLC from the global phase (Ph) 3 trial DUBLIN-3 (BPI-2358-103) with the plinabulin/docetaxel (Plin/Doc) combination versus Doc alone.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9090-9090.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9028-9028.	0.8	4
20	Outcomes of sintilimab plus pemetrexed and platinum (SPP) according to stage of disease in patients (pts) with locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase 3 ORIENT-11 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21157-e21157.	0.8	0
21	Phase Ib/IIa study evaluating the safety and clinical activity of osimertinib combined with anlotinib in EGFRm, treatment-naïve advanced NSCLC patients (AUTOMAN).. <i>Journal of Clinical Oncology</i> , 2022, 40, e21140-e21140.	0.8	1
22	Feasibility of Surgical Resection After Induction Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy for N2 Lung Adenocarcinomas. <i>Annals of Thoracic Surgery</i> , 2021, 111, 290-295.	0.7	3
23	EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study. <i>Clinical Lung Cancer</i> , 2021, 22, e395-e404.	1.1	4
24	Clinical significance of visceral pleural and lymphovascular invasion in surgically resected adenosquamous lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 59, 617-623.	0.6	7
25	Allogeneic V $\alpha$ 39V $\beta$ 2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. <i>Cellular and Molecular Immunology</i> , 2021, 18, 427-439.	4.8	122
26	Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2261-2274.	2.0	17
27	PIGF knockdown attenuates hypoxia-induced stimulation of cell proliferation and glycolysis of lung adenocarcinoma through inhibiting Wnt/ $\beta$ 2-catenin pathway. <i>Cancer Cell International</i> , 2021, 21, 18.	1.8	3
28	Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis. <i>Cell Death and Disease</i> , 2021, 12, 170.	2.7	13
29	FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor. <i>Life Sciences</i> , 2021, 268, 119022.	2.0	5
30	Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 652560.	1.3	8
31	Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 643-652.	0.5	123
32	Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery. <i>Lung Cancer</i> , 2021, 154, 124-130.	0.9	2
33	Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC. <i>Frontiers in Oncology</i> , 2021, 11, 671228.	1.3	13
34	Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. <i>British Journal of Cancer</i> , 2021, 125, 366-371.	2.9	71
35	First-line anlotinib-based combination treatment for patients with advanced non-small cell lung cancer: A three arms, prospective study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21073-e21073.	0.8	0
36	Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation. <i>Respiratory Research</i> , 2021, 22, 145.	1.4	5

#	ARTICLE	IF	CITATIONS
37	Therapeutic effect of DDR pathway with different functional annotations for immune checkpoint inhibitor.. Journal of Clinical Oncology, 2021, 39, 2611-2611.	0.8	1
38	Association between germline DNA damage repair-related genes mutation and tumor mutational burden in lung cancer patients.. Journal of Clinical Oncology, 2021, 39, e21163-e21163.	0.8	0
39	Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer.. Journal of Clinical Oncology, 2021, 39, e21072-e21072.	0.8	3
40	Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors.. Journal of Clinical Oncology, 2021, 39, e20568-e20568.	0.8	0
41	International consensus on severe lung cancerâ€”the first edition. Translational Lung Cancer Research, 2021, 10, 2633-2666.	1.3	6
42	Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 665484.	1.3	6
43	Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 â‰¥50%: Results of a Retrospective Study. Frontiers in Oncology, 2021, 11, 691519.	1.3	4
44	Immune-Related Adverse Events and Efficacyâ€”The More It Hurts, the Better It Works?. JAMA Oncology, 2021, 7, 944.	3.4	1
45	Occurrence of hypertension during thirdâ€”line anlotinib is associated with progressionâ€”free survival in patients with squamous cell lung cancer (<scp>SCC</scp>): A post hoc analysis of the <scp>ALTER0303</scp> trial. Thoracic Cancer, 2021, 12, 2345-2351.	0.8	5
46	Patterns of Recurrence and Survival Rate After Complete Resection of Pathological Stage N2 Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 675354.	1.3	1
47	Utility and Safety of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Diagnosis of Isolated Mediastinal Masses. Journal of Multidisciplinary Healthcare, 2021, Volume 14, 2047-2052.	1.1	0
48	Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations. Frontiers in Oncology, 2021, 11, 681429.	1.3	5
49	Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. Journal of Thoracic Oncology, 2021, 16, 2109-2120.	0.5	75
50	hsa_circ_0003222 accelerates stemness and progression of non-small cell lung cancer by sponging miR-527. Cell Death and Disease, 2021, 12, 807.	2.7	29
51	ctDNA-Profilng-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients. Frontiers in Genetics, 2021, 12, 723670.	1.1	9
52	Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment. International Immunopharmacology, 2021, 98, 107734.	1.7	5
53	Comparative Study of Pulmonary Combined Large-Cell Neuroendocrine Carcinoma and Combined Small-Cell Carcinoma in Surgically Resected High-Grade Neuroendocrine Tumors of the Lung. Frontiers in Oncology, 2021, 11, 714549.	1.3	3
54	Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial. Translational Lung Cancer Research, 2021, 10, 3793-3806.	1.3	5

#	ARTICLE	IF	CITATIONS
55	Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2021, 12, 708558.	2.2	9
56	TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 732125.	2.2	10
57	Effectiveness of anlotinib in patients with smallâ€cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study. <i>Thoracic Cancer</i> , 2021, 12, 3039-3045.	0.8	5
58	Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. <i>Cancer Biology and Medicine</i> , 2021, 18, 816-824.	1.4	18
59	A pharmacogenetics study of platinum-based chemotherapy in lung cancer: <i>ABCG2</i> polymorphism and its genetic interaction with <i>SLC31A1</i> are associated with response and survival. <i>Journal of Cancer</i> , 2021, 12, 1270-1283.	1.2	10
60	The Association Between PNPLA2 Methylation in Peripheral Blood and Early-Stage Lung Cancer in a Caseâ€Control Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 7919-7927.	0.9	2
61	Interstitial lung abnormalities: What do we know and how do we manage?. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1551-1561.	1.0	0
62	The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus. <i>Frontiers in Oncology</i> , 2021, 11, 745150.	1.3	2
63	Lung adenocarcinoma resistance to therapy with EGFRâ€tyrosine kinase inhibitors is related to increased expression of cancer stem cell markers SOX2, OCT4 and NANOG. <i>Oncology Reports</i> , 2020, 43, 727-735.	1.2	9
64	Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies. <i>International Journal of Cancer</i> , 2020, 146, 3124-3133.	2.3	40
65	Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 401-406.	1.2	18
66	Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery. <i>Lung Cancer</i> , 2020, 141, 72-77.	0.9	13
67	Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients. <i>Journal of International Medical Research</i> , 2020, 48, 030006051988727.	0.4	27
68	Going Beyond Results of the PEMBRO-RT Trial. <i>JAMA Oncology</i> , 2020, 6, 161.	3.4	0
69	Evaluating the diagnostic accuracy of a ctDNA methylation classifier for incidental lung nodules: protocol for a prospective, observational, and multicenter clinical trial of 10,560 cases. <i>Translational Lung Cancer Research</i> , 2020, 9, 2016-2026.	1.3	6
70	&lt;p&gt;The Association Between RAPSN Methylation in Peripheral Blood and Early Stage Lung Cancer Detected in Caseâ€Control Cohort&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 11063-11075.	0.9	9
71	Clinical Features and Outcomes Analysis of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 556194.	1.3	12
72	Tumour mutational burden in treatment-resistant tumours. <i>Lancet Oncology</i> , The, 2020, 21, e551.	5.1	3

#	ARTICLE	IF	CITATIONS
73	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology) Tj ETQq1 1 0.784314238T /Over	1.0	14
74	Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma. Translational Lung Cancer Research, 2020, 9, 1464-1471.	1.3	2
75	Schwann cells promote lung cancer proliferation by promoting the M2 polarization of macrophages. Cellular Immunology, 2020, 357, 104211.	1.4	15
76	Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer. Journal of Oncology, 2020, 2020, 1-7.	0.6	4
77	&lt;p&gt;Tyrosine Kinase Inhibitor-Related Hepatotoxicity in Patients with Advanced Lung Adenocarcinoma: A Real-World Retrospective Study&lt;/p&gt;. Cancer Management and Research, 2020, Volume 12, 3293-3299.	0.9	6
78	Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis. Targeted Oncology, 2020, 15, 337-345.	1.7	4
79	Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study. Targeted Oncology, 2020, 15, 175-184.	1.7	13
80	Does surgically resected smallâ€cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?. Thoracic Cancer, 2020, 11, 1239-1244.	0.8	7
81	CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients. Frontiers in Oncology, 2020, 10, 1049.	1.3	13
82	&lt;p&gt;Expression Level of Wnt5a Was Related to the Therapeutic Effects of First-Generation EGFR-TKIs&lt;/p&gt;. OncoTargets and Therapy, 2020, Volume 13, 5387-5394.	1.0	1
83	New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 631-645.	1.2	50
84	Effect of anlotinib as a thirdâ€or furtherâ€line therapy in advanced nonâ€small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial. Cancer Medicine, 2020, 9, 2621-2630.	1.3	19
85	Serum TNFRII: A promising biomarker for predicting the risk of subcentimetre lung adenocarcinoma. Journal of Cellular and Molecular Medicine, 2020, 24, 4150-4156.	1.6	1
86	The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303). Oncologist, 2020, 25, e870-e874.	1.9	36
87	Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Nonâ€small-cell Lung Cancer in China. Clinical Lung Cancer, 2020, 21, e355-e362.	1.1	6
88	Effect of anlotinib in advanced small cell lung cancer (SCLC) patients relapsed within three months after second-line treatment: A subgroup analysis from a randomized, double-blind phase II trial (ALTER) Tj ETQq0 0 0.8T /Overlock 10 T	0.8	10
89	Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study. International Journal of Clinical Oncology, 2020, 25, 1492-1498.	1.0	6
90	Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Nonâ€Small-Cell Lung Cancer During Crizotinib Treatment. Clinical Lung Cancer, 2019, 20, e631-e637.	1.1	7



#	ARTICLE	IF	CITATIONS
91	Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients. <i>Lung Cancer</i> , 2019, 135, 138-144.	0.9	13
92	Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma. <i>Targeted Oncology</i> , 2019, 14, 423-431.	1.7	3
93	Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 773-779.	1.6	10
94	Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line. <i>Frontiers in Oncology</i> , 2019, 9, 886.	1.3	20
95	Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER0303. <i>Thoracic Cancer</i> , 2019, 10, 551-556.	0.8	42
96	Development and validation of a predictive model for the diagnosis of solid solitary pulmonary nodules using data mining methods. <i>Journal of Thoracic Disease</i> , 2019, 11, 950-958.	0.6	13
97	Adjuvant Chemotherapy Improves Survival in Surgically Resected Stage IB Squamous Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1683-1689.	0.7	6
98	Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete Lobectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 2392-2400.	0.7	12
99	First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China. <i>Thoracic Cancer</i> , 2019, 10, 1043-1050.	0.8	2
100	Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib. <i>Targeted Oncology</i> , 2019, 14, 169-178.	1.7	17
101	Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells. <i>BMC Medical Genomics</i> , 2019, 12, 38.	0.7	28
102	Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases. <i>Journal of Cardiothoracic Surgery</i> , 2019, 14, 63.	0.4	3
103	Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study. <i>Lung Cancer</i> , 2019, 130, 18-24.	0.9	10
104	Genome-Wide Plasma Cell-Free DNA Methylation Profiling Identifies Potential Biomarkers for Lung Cancer. <i>Disease Markers</i> , 2019, 2019, 1-7.	0.6	44
105	Design of a prospective, multicenter, and cohort study of an innovative electromagnetic navigation bronchoscopy in diagnosing pulmonary nodules among Chinese population. <i>Journal of Thoracic Disease</i> , 2019, 11, 5592-5600.	0.6	7
106	The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial. <i>Translational Lung Cancer Research</i> , 2019, 8, 575-583.	1.3	27
107	Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study. <i>Oncologist</i> , 2019, 24, 157-e64.	1.9	79
108	Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma. <i>Thoracic Cancer</i> , 2019, 10, 249-255.	0.8	11

#	ARTICLE	IF	CITATIONS
109	The REACH Trial: A Randomized Controlled Trial Assessing the Safety and Effectiveness of the Spiration® Valve System in the Treatment of Severe Emphysema. <i>Respiration</i> , 2019, 97, 416-427.	1.2	53
110	Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. <i>European Respiratory Journal</i> , 2019, 53, 1801562.	3.1	61
111	Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation. <i>International Journal of Cancer</i> , 2019, 144, 2880-2886.	2.3	25
112	OCT4&SOX2-specific cytotoxic T lymphocytes plus programmed cell death protein 1 inhibitor presented with synergistic effect on killing lung cancer stem-like cells in vitro and treating drug-resistant lung cancer mice in vivo. <i>Journal of Cellular Physiology</i> , 2019, 234, 6758-6768.	2.0	11
113	Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9091-9091.	0.8	5
114	The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 195-195.	0.7	7
115	Application of endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal lymphangioma. <i>Annals of Translational Medicine</i> , 2019, 7, 450-450.	0.7	1
116	The efficacy of anlotinib in squamous cell carcinoma (SCC) patients with or without hypertension in ALTER0303: Anlotinib as a third-line therapy in patients with advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e20503-e20503.	0.8	0
117	Clinical outcomes of patients with or without common AEs in anlotinib cohort: Subgroup analysis of the ALTER0303 trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20507-e20507.	0.8	0
118	Clinicopathological characteristics with EGFR, ALK, ROS1 genetic alternation and prognostic analysis of primary lymphoepithelioma-like carcinoma. <i>Translational Cancer Research</i> , 2019, 8, 2350-2356.	0.4	0
119	Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening. <i>Lung Cancer</i> , 2018, 117, 20-26.	0.9	78
120	Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?. <i>Lung Cancer</i> , 2018, 117, 27-31.	0.9	13
121	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). <i>British Journal of Cancer</i> , 2018, 118, 654-661.	2.9	192
122	Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas. <i>Cancer</i> , 2018, 124, 2399-2406.	2.0	19
123	Predictors of recurrence and survival of pathological T1N0M0 invasive adenocarcinoma following lobectomy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1015-1023.	1.2	19
124	Utility of endobronchial ultrasound-guided transbronchial needle aspiration in diagnosing non-specific inflammatory intrathoracic lymphadenitis. <i>Clinical Respiratory Journal</i> , 2018, 12, 691-698.	0.6	5
125	High-resolution Computed Tomography Features Distinguishing Benign and Malignant Lesions Manifesting as Persistent Solitary Subsolid Nodules. <i>Clinical Lung Cancer</i> , 2018, 19, e75-e83.	1.1	35
126	A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 27-34.	1.1	21



#	ARTICLE	IF	CITATIONS
127	Risk factors of lymph node metastasis in patients with non-small cell lung cancer ≤ 2cm in size: monocentric population-based analysis. <i>Thoracic Cancer</i> , 2018, 9, 3-9.	0.8	31
128	Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1227-1235.e2.	0.4	62
129	Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing) Tj ETQq1 1 0.784314 rgBT /Over lung cancer. <i>Investigational New Drugs</i> , 2018, 36, 315-322.	1.2	42
130	Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment. <i>Cancer Biology and Medicine</i> , 2018, 15, 443.	1.4	29
131	The role of prophylactic cranial irradiation in surgically resected combined small cell lung cancer: a retrospective study. <i>Journal of Thoracic Disease</i> , 2018, 10, 3418-3427.	0.6	4
132	Screening for early stage lung cancer and its correlation with lung nodule detection. <i>Journal of Thoracic Disease</i> , 2018, 10, S846-S859.	0.6	19
133	Predicting malignancy of pulmonary ground-glass nodules and their invasiveness by random forest. <i>Journal of Thoracic Disease</i> , 2018, 10, 458-463.	0.6	30
134	Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer. <i>Lung Cancer</i> , 2018, 125, 245-252.	0.9	20
135	Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381880180.	0.8	18
136	Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review. <i>Targeted Oncology</i> , 2018, 13, 631-639.	1.7	2
137	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 122, 32-37.	0.9	32
138	Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2121-2129.	1.0	15
139	Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells. <i>Journal of Cancer</i> , 2018, 9, 367-374.	1.2	11
140	Adjuvant chemotherapy may improve prognosis after resection of stage I lung cancer with lymphovascular invasion. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 2006-2015.e2.	0.4	21
141	Hepatotoxicity in Advanced Lung Adenocarcinoma: A Retrospective Study of 2108 Cases. <i>Journal of Cancer</i> , 2018, 9, 1607-1613.	1.2	6
142	Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 1569.	3.4	388
143	Schwann Cells Augment Cell Spreading and Metastasis of Lung Cancer. <i>Cancer Research</i> , 2018, 78, 5927-5939.	0.4	54
144	Subgroup analysis of histology in ALTER0303: Anlotinib hydrochloride as 3rd line and further line treatment in refractory advanced NSCLC patients (pts).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9080-9080.	0.8	7

#	ARTICLE	IF	CITATIONS
145	OS outcomes to anlotinib in patients (pts) with refractory NSCLC of both wild-type (WT) and mutant EGFR. <i>Journal of Clinical Oncology</i> , 2018, 36, e21013-e21013.	0.8	3
146	Subgroup analysis of elderly patients (pts) in ALTER0303: Anlotinib hydrochloride as 3 <sup>rd</sup> -line and further line treatment in refractory advanced NSCLC pts from a randomized, double-blind, placebo-controlled phase III ALTER0303 trial. <i>Journal of Clinical Oncology</i> , 2018, 36, e21181-e21181.	0.8	3
147	Efficiency of anlotinib hydrochloride as 3 <sup>rd</sup> line treatment in patients (pts) from a randomized, double-blind, placebo-controlled phase III trial, an exploratory subgroup analysis of ALTER0303 trial for the previous therapy strategy effect. <i>Journal of Clinical Oncology</i> , 2018, 36, e21182-e21182.	0.8	1
148	Genetic polymorphism of <i>SLC31A1</i> is associated with clinical outcomes of platinum-based chemotherapy in non-small-cell lung cancer patients through modulating microRNA-mediated regulation. <i>Oncotarget</i> , 2018, 9, 23860-23877.	0.8	12
149	Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. <i>Lung Cancer</i> , 2017, 104, 119-125.	0.9	41
150	Predicting the recurrence risk factors and clinical outcomes of peripheral pulmonary adenocarcinoma with wedge resection. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1043-1051.	1.2	10
151	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016) <i>TJ ETQq1</i> 10,784314rgBT /Ove 0.7 34	1.0	34
152	Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy. <i>Carcinogenesis</i> , 2017, 38, 419-424.	1.3	10
153	Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial. <i>International Journal of Cancer</i> , 2017, 141, 1249-1256.	2.3	96
154	The indication of completion lobectomy for lung adenocarcinoma after wedge resection during surgical operation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2095-2104.	1.2	12
155	Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small cell lung cancer patients with EGFR mutations. <i>International Journal of Cancer</i> , 2017, 140, 1645-1652.	2.3	34
156	Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 663-672.	0.5	100
157	Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer. <i>Scientific Reports</i> , 2017, 7, 11785.	1.6	28
158	EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. <i>Lung Cancer</i> , 2017, 113, 37-44.	0.9	99
159	Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 347-353.	0.5	50
160	Application of Quantitative Autofluorescence Bronchoscopy Image Analysis Method in Identifying Bronchopulmonary Cancer. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 482-487.	0.8	6
161	The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2335-2340.	1.0	21
162	Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells. <i>Yonsei Medical Journal</i> , 2017, 58, 581.	0.9	0

#	ARTICLE	IF	CITATIONS
163	Solid predominant histologic subtype and early recurrence predict poor postrecurrence survival in patients with stage I lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 7050-7058.	0.8	19
164	The Advent of Ultra-high Volume Thoracic Surgical Centers in Shanghai. <i>World Journal of Surgery</i> , 2017, 41, 2758-2768.	0.8	15
165	Gprc5a-knockout mouse lung epithelial cells predicts ceruloplasmin, lipocalin 2 and periostin as potential biomarkers at early stages of lung tumorigenesis. <i>Oncotarget</i> , 2017, 8, 13532-13544.	0.8	16
166	PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC). <i>Oncotarget</i> , 2017, 8, 26845-26857.	0.8	55
167	Serum dickkopf-1 as a clinical and prognostic factor in non-small cell lung cancer patients with bone metastases. <i>Oncotarget</i> , 2017, 8, 79469-79479.	0.8	15
168	MicroRNA-107-5p suppresses non-small cell lung cancer by directly targeting oncogene epidermal growth factor receptor. <i>Oncotarget</i> , 2017, 8, 57012-57023.	0.8	28
169	Pathologic subtype-defined prognosis is dependent on both tumor stage and status of oncogenic driver mutations in lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 82244-82255.	0.8	7
170	Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 108522-108533.	0.8	16
171	Molecular profiling identifies prognostic markers of stage IA lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 74846-74855.	0.8	7
172	MFN2 might be a risk factor for lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13007-e13007.	0.8	1
173	Isolation and expansion of OCT4/Sox2 specific cytotoxic T lymphocytes in vitro.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14578-e14578.	0.8	0
174	How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitor for lung adenosquamous cell carcinoma harboring EGFR mutation? A bicenter research and pooled analysis of published reports.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20571-e20571.	0.8	0
175	Accuracy and clinical influence of plasma EGFR mutation detection in management of advanced lung adenocarcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 9559-9566.	0.5	0
176	Î2-catenin inhibitors suppress cells proliferation and promote cells apoptosis in PC9 lung cancer stem cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 11968-11978.	0.5	5
177	The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6479-6484.	1.0	3
178	MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2016, 11, e0150467.	1.1	7
179	Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2031-2040.	1.2	36
180	Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1837-1845.	1.2	21

#	ARTICLE	IF	CITATIONS
181	Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS in advanced non-small cell lung cancer. <i>Gene</i> , 2016, 591, 58-64.	1.0	32
182	EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer. <i>Oncology Letters</i> , 2016, 11, 2371-2378.	0.8	14
183	Sonographic Features of Endobronchial Ultrasound in Differentiation of Benign Lymph Nodes. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 2785-2793.	0.7	17
184	<i>RICTOR</i> polymorphisms affect efficiency of platinum-based chemotherapy in Chinese non-small-cell lung cancer patients. <i>Pharmacogenomics</i> , 2016, 17, 1637-1647.	0.6	5
185	Downregulation of HIF-1 $\alpha$ inhibits the proliferation and invasion of non-small cell lung cancer NCI-H157 cells. <i>Oncology Letters</i> , 2016, 11, 1738-1744.	0.8	23
186	ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1682-1689.	0.5	151
187	EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation. <i>Scientific Reports</i> , 2016, 6, 36371.	1.6	6
188	Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 265.	1.1	34
189	Transcriptional profiling revealed the anti-proliferative effect of MFN2 deficiency and identified risk factors in lung adenocarcinoma. <i>Tumor Biology</i> , 2016, 37, 8643-8655.	0.8	10
190	Surgical Therapy for Bilateral Multiple Primary Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2016, 101, 1145-1152.	0.7	51
191	Role of miR-497 in VEGF-A-mediated cancer cell growth and invasion in non-small cell lung cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 70, 118-125.	1.2	40
192	EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. <i>Lung Cancer</i> , 2016, 96, 87-92.	0.9	81
193	Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1325-1330.	1.2	20
194	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 309-314.	1.1	13
195	Lentivirus-mediated knockdown of CTDP1 inhibits lung cancer cell growth in vitro. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 723-732.	1.2	6
196	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation. <i>Thoracic Cancer</i> , 2016, 7, 614-618.	0.8	3
197	Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8566-8566.	0.8	5
198	First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9041-9041.	0.8	7

#	ARTICLE	IF	CITATIONS
199	Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer. <i>PLoS Genetics</i> , 2016, 12, e1005895.	1.5	144
200	Two-stage induced differentiation of OCT4+/Nanog+ stem-like cells in lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 68360-68370.	0.8	20
201	Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations. <i>Oncotarget</i> , 2016, 7, 68442-68448.	0.8	13
202	MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 83051-83059.	0.8	12
203	Peripheral blood-based genetic signatures for early diagnosis of micro-nodular lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20051-e20051.	0.8	0
204	First-line icotinib in elderly patients with non-small cell lung cancer harboring active EGFR mutation: A multi-center, single-arm study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20519-e20519.	0.8	0
205	Establishment and management of a lung cancer biobank in Eastern China. <i>Thoracic Cancer</i> , 2015, 6, 58-63.	0.8	4
206	Current small cell lung cancer treatment in China. <i>Thoracic Cancer</i> , 2015, 6, 233-238.	0.8	26
207	Wnt blockers inhibit the proliferation of lung cancer stem cells. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2399.	2.0	31
208	Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0129232.	1.1	11
209	Epithelial neoplasia coincides with exacerbated injury and fibrotic response in the lungs of Gprc5a knockout mice following silica exposure. <i>Oncotarget</i> , 2015, 6, 39578-39593.	0.8	10
210	Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis. <i>Molecular and Clinical Oncology</i> , 2015, 3, 420-424.	0.4	5
211	Lung Tumor Suppressor GPRC5A Binds EGFR and Restrains Its Effector Signaling. <i>Cancer Research</i> , 2015, 75, 1801-1814.	0.4	53
212	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2197-2204.	0.8	323
213	Determining Factors in Diagnosing Pulmonary Sarcoidosis by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. <i>Annals of Thoracic Surgery</i> , 2015, 99, 441-445.	0.7	31
214	Sonographic Features of Endobronchial Ultrasonography Predict Intrathoracic Lymph Node Metastasis in Lung Cancer Patients. <i>Annals of Thoracic Surgery</i> , 2015, 100, 1203-1209.	0.7	40
215	An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8039-8039.	0.8	2
216	HSG-MLF1IP axis as potential targets for lung adenocarcinoma treatment.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13591-e13591.	0.8	0

#	ARTICLE	IF	CITATIONS
217	Electromagnetic navigation bronchoscopy guided injection of methylene blue combined with hookwire for preoperative localization of small pulmonary lesions in thoracoscopic surgery. <i>Journal of Thoracic Disease</i> , 2015, 7, E652-6.	0.6	12
218	Association of XPC Polymorphisms and Lung Cancer Risk: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e93937.	1.1	23
219	Lung cancer-derived Dickkopf1 is associated with bone metastasis and the mechanism involves the inhibition of osteoblast differentiation. <i>Biochemical and Biophysical Research Communications</i> , 2014, 443, 962-968.	1.0	23
220	Novel Association Between CD74 Polymorphisms and Hematologic Toxicity in Patients With NSCLC After Platinum-Based Chemotherapy. <i>Clinical Lung Cancer</i> , 2014, 15, 67-78.e12.	1.1	4
221	A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2014, 86, 207-212.	0.9	47
222	Randomized, placebo-controlled study of vinorelbine plus cisplatin with celecoxib and serum VEGF before treatment as a biomarker for patients with advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19066-e19066.	0.8	0
223	Construction and efficacy identification of the lentiviral vector harboring RNAi based on the <i>hyperplasia suppressor gene</i> (<i>HSG</i>).. <i>Journal of Clinical Oncology</i> , 2014, 32, e22177-e22177.	0.8	0
224	Clinical analysis of Gefitinib in the treatment of stage IV lung adenocarcinoma with unknown EGFR gene mutations. <i>Thoracic Cancer</i> , 2013, 4, 433-439.	0.8	1
225	Association of CASP7 Polymorphisms and Survival of Patients With Non-small Cell Lung Cancer With Platinum-Based Chemotherapy Treatment. <i>Chest</i> , 2012, 142, 680-689.	0.4	8
226	Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 466-475.	5.1	236
227	Erlotinib as neoadjuvant treatment in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation (NCT01217619, ESTERN).. <i>Journal of Clinical Oncology</i> , 2012, 30, e17551-e17551.	0.8	1
228	Update of a phase III trial of adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients with completely resected stage IB-IIIa non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, e18013-e18013.	0.8	0
229	Lung cancer and benign lung diseases in patients with serious vitamin D deficiency in eastern China.. <i>Journal of Clinical Oncology</i> , 2012, 30, e12010-e12010.	0.8	0
230	NAD(P)H: Quinone oxidoreductase 1 (<i>NQO1</i>) C609T polymorphism and lung cancer risk: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1551-1551.	0.8	0
231	Modulation of regulatory dendritic cell polarization in cancer by paclitaxel.. <i>Journal of Clinical Oncology</i> , 2012, 30, e21001-e21001.	0.8	0
232	Five vitamin D receptor polymorphisms (FokI, BsmI, ApaI, TaqI, and Cdx2) and lung cancer risk.. <i>Journal of Clinical Oncology</i> , 2012, 30, e12013-e12013.	0.8	0
233	Inhibition of tumor cell growth, invasion, and metastasis by SIM-89, a novel inhibitor of HGF receptor tyrosine kinases.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13528-e13528.	0.8	0
234	Circulating endothelial cells and serum caspase-cleaved CK18 to predict for response and survival in non-small cell lung cancer patients receiving endostatin and paclitaxel-carboplatin combined chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, e18088-e18088.	0.8	0



#	ARTICLE	IF	CITATIONS
235	CEA levels and EGFR mutations associated with patients in nonsmokers lung cancer.. Journal of Clinical Oncology, 2012, 30, e18038-e18038.	0.8	0
236	Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Lung Cancer, 2011, 72, 238-243.	0.9	47
237	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1104-1109.	0.5	75
238	Role of endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of bronchogenic carcinoma: Experience of a single institution in China. Thoracic Cancer, 2010, 1, 28-34.	0.8	13
239	Gefitinib or Carboplatin+Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine, 2009, 361, 947-957.	13.9	7,606
240	Current research on consolidation therapy and follow-up health care in advanced non-small cell lung cancer patients. Chinese Journal of Clinical Oncology, 2008, 5, 146-149.	0.0	0
241	Prognostic factors in patients with stage IV non-small cell lung cancer. Chinese-German Journal of Clinical Oncology, 2006, 5, 319-323.	0.1	3